Pharma BD Deal Intelligence
Takeda acquired Ariad for $5.2B for oncology and hematology divisions.
Takeda announced acquisition of all outstanding shares in ARIAD for $24 per share in cash, enterprise value of approximately $5.2 billion, gaining brigatinib…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda acquired Ariad for $5.2B for oncology and hematology divisions.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals (this deal) | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2003 deals · Takeda Pharmaceutical Company Ltd. deals · Oncology deals